Singapore Hepatology Conference 2026

31 August to 3 September 2026

6.30pm to 10.30pm

Register for Online Meeting

You need to first Register for Singapore Hepatology Conference

Singapore Hepatology Conference 2026 Scientific Programme

Speakers names will be added soon.

August, 2026

31

Programme	Time (SGT)
Chronic Hepatitis B And D
Chairs
Opening comments and introduction Prof. Seng Gee Lim, National University Health System, Singapore View Bio	06.30 pm to 06.40 pm
CHB Grey zone: clinical significance Adj Assoc. Prof. Daniel Huang, National University Health System, Singapore View Bio	06.40 pm to 07.00 pm
Landscape of Hepatitis B cure in 2026 Prof. Man Fung Yuen, Hong Kong University, Hong Kong View Bio	07.00 pm to 07.20 pm
GSK Symposium	7.20pm to 7.50 pm
Q&A	7.50pm to 8.15pm
Break	8.15 pm to 8.30 pm
Gene therapy for CHB Prof. Ed Gane, University of Auckland, New Zealand View Bio	8.30 pm to 8.50 pm
Immune suppression and HBV Prof. Teerha Piratvisuth, Prince of Songkla University, Thailand View Bio	08.50 pm to 09.10 pm
Management of severe hepatitis B Flares Prof. Seng Gee Lim, National University Health System, Singapore View Bio	09.10 pm to 09.30 pm
Delta Hepatitis Update Prof. Pietro Lampertico, University of Milan, Italy View Bio	09.30 pm to 9.50 pm
Q&A	9.50 pm to 10.15 pm
Close	10.15pm

September, 2026

1

Programme	Time (SGT)
MASLD & MASH
Opening comments and Introduction Adj. Prof. Mark Muthiah, National University Health System, Singapore View Bio	06.30pm to 06.45pm
Phenotype-genotype interactions in MASLD: A south east asian perspective Prof. Chan Wah Kheong, University of Malaya, Malaysia View Bio	06.45pm to 07.10pm
Screening for MASLD in the community: are our protocols ready? Prof. Hannes Hagstrom, Karolinska Institute, Sweden	07.10pm to 07.35pm
Q&A	07.35pm to 08.00pm
Break	08.00pm to 08.20pm
Debate: MASLD and MASH has lost its relevance – we should only be screening for fibrosis (con) Prof. Vincent Wong, Chinese University of Hong Kong, Hong Kong View Bio	08.20pm to 08.40pm
Debate: MASLD and MASH has lost its relevance – we should only be screening for fibrosis (pro) TBD	08.40pm to 09.00pm
Q&A	09.00pm to 09.20pm
A practical approach to treatment of MASH (pre-recorded) Prof. Jacob George, University of Sydney, Australia	09.20pm to 9.45pm
Extra-hepatic caridometabolic consequences in MASLD: when to screen TBD	09.45pm to 10.10pm
Q&A	10.10pm to 10.30pm

September, 2026

2

Programme	Time (SGT)
Hepatocellular carcinoma (HCC)
Opening comments and Introduction Adj. Assoc. Prof. Daniel Huang, National University Health System, Singapore View Bio	06.30 pm to 06.45 pm
Prevention and surveillance for hepatocellular carcinoma in chronic hepatitis B Prof. Grace Wong, Chinese University of Hong Kong, Hong Kong	06.45 pm to 07.10 pm
Conversion therapy for initially unresectable HCC Prof. Masatoshi Kudo, Kindai University, Japan View Bio	07.10 pm to 07.35 pm
Precision medicine for HCC Prof. Luca Valenti, University of Milan, Italy	07.35 pm to 08.00 pm
Q&A	08.00 pm to 08.20 pm
Break	8.20pm to 8.30pm
Locoregional and systemic therapy in intermediate HCC Prof. Pierce Chow, Duke-NUS Graduate School of Medicine, Singapore View Bio	08.30 pm to 08.55 pm
Updates in systemic therapy for HCC Prof. Arndt, Vogel, Hannover Medical School, Germany	08.55 pm to 09.20 pm
MASLD-related HCC: risk prediction, surveillance, and prevention TBD	09.20 pm to 09.35 pm
Q&A	09.35 pm to 10.00 pm

September, 2026

3

Programme	Time (SGT)
Advanced Liver Diseases
Opening comments and Introduction – Adj A/Prof Lee Guan Huei National University Health System, Singapore View Bio	06.30 pm to 06.45 pm
“Alcohol-related liver disease and transplantation in the Asia-Pacific: practical lessons from an Australian national transplant programme” Dr Anastasia Volovet, Sydney Local Health District, Australia	06.45 pm to 07.10 pm
“MetALD in Singapore: building a clinic pathway—non-invasive risk stratification, multidisciplinary care, and when to escalate” Adj. Prof. Mark Muthiah, National University Health System, Singapore View Bio	07.10 pm to 07.35 pm
“Treating Alcohol Use Disorder as core liver care: pharmacotherapy,relapse prevention, and shared-care models between hepatology and addiction services” Dr. Charles Mak, IMH/NAMS, Singapore	07.35 pm to 08.00 pm
Q & A Session	08.00 pm to 08.30 pm
Break	08.30 pm to 08.45 pm
“Alcohol-Related Liver Disease in 2026: a holistic, personalised approach —linking AUD treatment, risk stratification, and emerging therapies” Prof. Ramon Bataller, Hospital Clinic De Barcelona, Spain	08.45 pm to 09.10 pm
“ALD and liver transplantation: from early LT for severe AAH to long-term outcomes—what systems must change” TBD	09.10 pm to 09.35 pm
“MetALD and the new SLD nomenclature: operationalising alcohol quantification, classification, and clinical decision-making” TBD	09.35 pm to 10.00 pm
Q & A Session	10.00 pm to 10.30 pm
Close	10.30 pm

Who Should Attend?

The Singapore Hepatology Conference programme is designed for busy clinicians, basic and translational researchers, nurse practitioners, pharmacists, from Asia, the Indian Sub-continent, Australia and New Zealand, to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology.

Our Attendees Include:

Hepatology experts.
Clinical, basic, and translational researchers.
Specialists who diagnose and treat liver disease, including gastroenterologists, surgeons, clinical pathologists, anesthesiologists, and radiologists.
Primary care physicians.
Nurse practitioners, registered nurses, physician assistants, pharmacists, and other allied health professionals in hepatology and the disciplines listed above.
Trainees, and students in the disciplines listed above.